公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
公司地址 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
電話號碼 +1 724 514-1800
傳真號碼 --
公司網頁 https://www.viatris.com
員工數量 30000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Scott A. Smith Director and Chief Executive Officer 美元 1.45M 02/04/2026
Mr. Matthew J. Maletta Chief Legal Officer -- 03/02/2026
Mr. Paul B. Campbell Interim Chief Financial Officer, Chief Accounting Officer and and Corporate Controller -- 04/05/2026
Dr. Corinne Le Goff, Pharm.D. Chief Commercial Officer 美元 899.33K 02/04/2026
Mr. Andrew Enrietti Chief Administrative and Transformation Officer 美元 684.90K 02/04/2026
Mr. Matthew Maletta Chief Legal Officer -- 02/04/2026
 
董事會成員
董事會 職務 更新日期
Ms. Elisha W. Finney Independent Director 02/04/2026
Mr. James M. Kilts Independent Director 02/04/2026
Mr. Wyllie Don Cornwell Independent Director 02/04/2026
Mr. Mark W. Parrish Vice Chairman of the Board 02/04/2026
Mr. Scott A. Smith Director and Chief Executive Officer 02/04/2026
Ms. Melina E. Higgins Chairman of the Board 02/04/2026
Mr. David S. Simmons Independent Director 02/04/2026
Ms. JoEllen Lyons Dillon Independent Director 02/04/2026
Dr. Michael Severino, M.D. Independent Director 02/04/2026
Dr. Rogerio Vivaldi Coelho, M.B.A.,M.D. Independent Director 02/04/2026
Mr. Richard A. Mark, C.P.A. Independent Director 02/04/2026
Mr. Leo Groothuis Independent Director 02/04/2026
Mr. Frank D’Amelio Independent Director 02/04/2026
 
所屬ETF (更新日期: 14/11/2026 02:19)
代號 名稱 佔比% ▼ 持有日期
SPXTProShares S&P 500® ex-Technology0.001%30/10/2026
JDIVJPMorgan US Dividend ETF0.001%31/08/2022
HCMTDirexion HCM Tactical EnhU.S.EqStratETF0.001%31/10/2026
SFYSoFi Select 500 ETF0.001%30/10/2026
BSEPInnovator US Equity Buffer ETF-Sep0.001%30/10/2026
PBPInvesco S&P 500 BuyWrite ETF0.001%30/10/2026
TSPYTappAlpha S&P 500 Growth & Daily Inc ETF0.001%30/10/2026
DFVEDoubleLine Fortune 500 Equal Weight ETF0.001%29/10/2026
BOCTInnovator U.S. Equity Buffer ETF™ Oct0.001%30/10/2026
XMAGDefiance Large Cap ex-Mag 7 ETF0.0005%30/10/2026
STXVStrive 1000 Value ETF0.0004%30/10/2026
IGDVoya Global Equity Dividend&Premium Opp0.0004%30/09/2026
XUDVFranklin U.S. Dividend Bstr Idx ETF0.0004%30/10/2026
TOVJLens 500 Jewish Advocacy U.S. ETF0.0004%30/10/2026
SPUUDirexion Daily S&P 500® Bull 2X ETF0.0004%31/10/2026
GSPYGotham Enhanced 500 ETF0.0004%30/10/2026
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.0003%30/10/2026
ABCSAlpha Blue Capital US Sm-Md Cp Dyn ETF0.0003%30/10/2026
LGDXIntech S&P Large Cap Diversified Alp ETF0.0003%30/10/2026
BRSMMFS Blended Research Small-Mid Cap ETF0.0003%30/10/2026
  1    2    3    4    5    6    7    8    9    10   11    12    13    14  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.